Journal article
Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis
W Leung, G Kvizhinadze, N Nair, T Blakely
Plos Medicine | PUBLIC LIBRARY SCIENCE | Published : 2016
Abstract
Background: The anti–human epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab improves outcomes in patients with node-positive HER2+ early breast cancer. Given trastuzumab’s high cost, we aimed to estimate its cost-effectiveness by heterogeneity in age and estrogen receptor (ER) and progesterone receptor (PR) status, which has previously been unexplored, to assist prioritisation. Methods and Findings: A cost-utility analysis was performed using a Markov macro-simulation model, with a lifetime horizon, comparing a 12-mo regimen of trastuzumab with chemotherapy alone using the latest (2014) effectiveness measures from landmark randomised trials. A New Zealand (NZ) health..
View full abstractGrants
Awarded by Health Research Council of New Zealand
Funding Acknowledgements
WL, GK, NN & TB received funding from the Health Research Council of New Zealand (www.hrc.govt.nz) grant 10/248. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.